OA05.07 Prognostic Value of Circulating Tumor Cells in Limited-Disease Small Cell Lung Cancer Patients Treated on the CONVERT Trial

Abstract

57% (95% CI 52-61), median survival was 29 months vs. 30 months in the elderly vs. younger group respectively. Hazard ratios for overall survival and progression free survival were 1.15 (95% CI 0.84-1.59; log-rank p¼0.38) and 1.04 (95% CI 0.76-1.41; log-rank p¼0.81) respectively. In the elderly group median survival was not significantly different in patients who received once vs. twice daily radiotherapy (p¼0.91). Conclusion: Radiotherapy treatment delivery was higher in the younger group but toxicity and survival rates were similar in elderly compared to younger patients. Concurrent chemo-radiotherapy with modern radiotherapy techniques is a treatment option for elderly patients with good performance status.

The clinical utility of circulating tumour cells in patients with small cell lung cancer

“…The median OS of all patients on the study was 30 months (95% CI, 24-34 months) in the twice daily treatment group and 25 months (95% CI, 21-31 months) in the once daily treatment group, which was not a statistically significant difference (53). Studies such as this will aid future patient stratification in clinical trials (52,54).…”

“…CTC number was highly prognostic for survival and the most significant threshold to discriminate good from poor outcomes was >15 CTCs/7.5mL of blood. All patients with >15 CTC at baseline progressed and died within 2 years of follow up (52). The median OS of all patients on the study was 30 months (95% CI, 24-34 months) in the twice daily treatment group and 25 months (95% CI, 21-31 months) in the once daily treatment group, which was not a statistically significant difference (53).…”